| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | Crystalys Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $335M | Series B | 7/22/2026 | $130M | $568.22M | $1.23 | Frazier Life Sciences, Wellington Management, HBM Healthcare Investments, Soleus Capital, Cormorant Asset Management, Trails Edge Capital Partners, Pivotal bioVenture Partners, KCap Biotechnology, Novo Holdings, SR One, Catalys Pacific, Perceptive Advisors, Lightstone Ventures, AN Venture Partners, Abrdn, KB Investments, Pontifax, Longwood Fund, Alexandria Venture Investments, Wedbush Healthcare Partners, Prebys Ventures | ||||
 | Genesis Molecular AI | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $340.28M | Series B-3 | 5/20/2026 | $40M | $806.79M | $9.33 | Incyte | ||||
 | Latigo Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $287.9M | Series B | 3/17/2025 | $150M | $525.73M | $1.57 | Blue Owl Capital, Deep Track Capital, Access Biotechnology, Qatar Investment Authority, Cormorant Asset Management, Sanofi Ventures, Rock Springs Capital, UPMC Enterprises, Kern Capital, Westlake Village BioPartners, Foresite Capital, 5AM Ventures, Alexandria Venture Investments | ||||
 | Neurelis | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $247.94M | Series D | 3/9/2021 | $114.76M | $544.18M | $3.15 | Cormorant Asset Management, Decheng Capital, LYZZ Capital, HBM Healthcare Investments, Philos & Partners SA | ||||
 | Neurona Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $342.29M | Series F | 4/3/2025 | $101.71M | $578.63M | $2.06 | Fidelity, The Column Group, Soleus Capital, Viking Global Investors, Cormorant Asset Management, Schroders Capital, LYFE Capital, Euclidean Capital, UCB Ventures, Willett Advisors, UC Investments, YK Bioventures, Berkeley Frontier Fund, Ysios Capital, Alexandria Venture Investments, Spur Capital Partners | ||||
 | Nusano | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $474.68M | Series D-1 | 4/21/2026 | $180M | $655.01M | $1.25 | Undisclosed Investors | ||||
 | Paradigm Health | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $281M | Series B-1 | 12/4/2025 | $57.73M | $505.1M | $1.00 | ARCH Venture Partners, DFJ Growth, F-Prime Capital, General Catalyst, GV, Lux Capital, Mubadala Capital, BrightEdge | ||||
 | Scorpion Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $1.02B | Series C-2 | 7/16/2024 | $24.31M | $821.83M | $2.54 | Frazier Life Sciences, Lightspeed Venture Partners, Willett Advisors, Omega Funds, Vida Ventures, Atlas Venture, Abingworth, Fidelity, Boxer Capital, EcoR1 Capital, Surveyor Capital, Invus, Wellington Management, Nextech Invest, OrbiMed, Logos Capital, Woodline Partners LP, Casdin Capital | ||||
 | Shoreline Biosciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $186M | Series B | 11/2/2021 | $140M | $527.99M | $10.07 | Ally Bridge Group, Eventide Asset Management, BeiGene, Irving Investors, Kingdon, NS Investment, Piper Heartland Healthcare Capital, Superstring, BVF Partners, Commodore Capital, Cormorant Asset Management, Janus Henderson Investors, Kite, Stork Capital, Wedbush Healthcare Partners | ||||
 | Abpro | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $69.53M | Series F | 3/30/2022 | $2M | $628.78M | $18.00 | Undisclosed Investors | ||||
 | Accutar Biotechnology | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $207.47M | Series B+4 | 8/20/2021 | $80M | $987.52M | $77.58 | Undisclosed Investors | ||||
 | Candid Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $370M | Series B | 9/9/2024 | $190.26M | $660.51M | $1.20 | Venrock, Fairmount Partners, TCG Crossover Management, venBio Partners, Foresite Capital, Third Rock Ventures, Fidelity, Samsara BioCapital, Qiming Venture Partners, OrbiMed, Boxer Capital, Redmile Group, Vida Ventures, Two River, Franklin Templeton, LifeSci Venture Partners, Mirae Asset Capital Life Science, Polaris Partners, Soleus Capital | ||||
 | Carmot Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $594.61M | Series E | 5/25/2023 | $150M | $696.68M | $23.01 | Deep Track Capital, 5AM Ventures, Franklin Templeton, Frazier Life Sciences, Janus Henderson Investors, Millenium Management, TCGX, Venrock Healthcare Capital Partners, RA Capital Management, The Column Group, Willett Advisors | ||||
 | Embark | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $94.55M | Series B | 7/26/2021 | $75M | $759.47M | $16.96 | SoftBank, F-Prime Capital, SV Angel, Slow Ventures, Freestyle Capital, Third Kind Venture Capital | ||||
 | ReCode Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $397.77M | Series B | 9/23/2025 | $290M | $588.16M | $9.23 | Matrix Capital Management, Pfizer Ventures, EcoR1 Capital, Sanofi Ventures, Tekla Capital Management, Superstring Capital, NS Investment, OrbiMed, Vida Ventures, MPM Capital, Colt Ventures, Hunt Technology Ventures, Osage University Partners, Bayer, Amgen, CF Foundation | ||||
 | Valo | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $406.25M | Series B | 3/9/2021 | $310M | $919.92M | $5.88 | PSP Investments, Flagship Pioneering, Invus Public Equities, HBM Healthcare Investments, Atinum Investment, Mirae Asset Capital, Koch Disruptive Technologies | ||||
 | Enable Injections | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $102.38M | Series B-1 | 1/6/2026 | $30M | $966.49M | $20.02 | Sanofi | ||||
 | Endeavor BioMedicines | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $295.58M | Series C | 4/24/2024 | $132.58M | $676.04M | $6.52 | AyurMaya, Fidelity Management & Research Company, Invus, SymBiosis, Velosity Capital, Woodline Partners, Abrdn Inc, Ally Bridge Group, Avidity Partners, Eckuity Capital, Longitude Capital, Omega Funds, Perceptive Advisors, Piper Heartland Healthcare Capital, Silver Arch Bio, T. Rowe Price Associates | ||||
 | RayzeBio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $795.51M | Series D | 9/13/2022 | $159.75M | $599.64M | $2.50 | Viking Global Investors, Sofinnova Investments, Wellington Management, Ally Bridge Group, Sands Capital, Laurion Capital Management, Soleus Capital | ||||
 | Strata Oncology | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $128.35M | Series A-3 | 7/28/2021 | $84.92M | $561.3M | $34.88 | Wellington Management, Cormorant Asset Management, Monashee Investment Management, Highside Capital Management, Pfizer Ventures, Merck Global Health Innovation Fund, Arboretum Ventures, Deerfield Management, Baird Capital, Renaissance Venture Capital | ||||
 | Upstream Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $800M | Series B | 6/8/2023 | $200M | $676.16M | $17.00 | Enavate Sciences, Venrock Healthcare Capital Partners, Bain Capital Life Sciences, Wellington Management, OrbiMed, Access Biotechnology, Decheng Capital, Altshuler Shaham Provident Funds Ltd., TCG X, HBM Healthcare Investments, Omega Funds, Samsara BioCapital | ||||
 | InterVenn | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $245.77M | Series C | 8/2/2021 | $201.27M | $685.15M | $8.83 | A.G. Hill Partners, Amplify Partners, Anzu Partners, Genoa Ventures, Heritage Provider Network, Highside Capital Management, Irving Investors, Softbank Group, True Ventures | ||||
 | Profluent | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $150M | Series B | 11/19/2025 | $106M | $502.78M | $34.07 | Altimeter Capital, Bezos Expeditions, Spark Capital, Insight Partners, Air Street Capital | ||||
 | Amylyx | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $203.25M | Series C-1 | 7/20/2021 | $107.33M | $541.01M | $10.27 | Viking Global Investors, Bain Capital Life Sciences, Perceptive Advisors, Rock Springs Capital, Woodline Partners, Marshall Wace, Tybourne Capital Management, Verition Fund Management, aMoon Fund, Falcon Edge, Morningside Ventures, 683 Capital Management, Belinda Termeer, Polaris Founders Capital | ||||